INmune Targets Brain Injury-Linked Alzheimer’s
BOCA RATON, Fla., July 15, 2026 INmune Bio announced the publication of a peer-reviewed preclinical study in the Journal...
Neuroinflammation
Advertisement
CervoMed Reports Positive Clinical, Biomarker and MRI Data for Neflamapimod at AAIC 2026
BOSTON, July 14, 2026 CervoMed presented new clinical, plasma biomarker, pharmacokinetic, and imaging analyses at the Alzheimer’s Association International...
Longeveron Reports Positive Phase 2a Laromestrocel Data
MIAMI, July 13, 2026 Longeveron announced new analyses from its Phase 2a CLEAR MIND clinical trial demonstrating that its...
Vandria Reports Positive Phase 1 VNA-318 Data
LAUSANNE, Switzerland, July 13, 2026 Vandria announced new Phase 1 clinical data demonstrating that its investigational small molecule VNA-318...
Vaccinex Showcases Pepinemab Biomarker Results
ROCHESTER, N.Y., July 8, 2026 Vaccinex announced that it will present new biomarker findings from its Phase 1b/2 SIGNAL-AD...
Advertisements
INmune Bio Reports Positive Phase 2 XPro Data
INmune Bio, BOCA RATON, Fla., July 9, 2026 INmune Bio Inc. announced positive new imaging findings from its Phase...
CervoMed Presents Neflamapimod DLB Data at AAIC
BOSTON, July 6, 2026 CervoMed Inc. announced that new clinical findings on its investigational therapy neflamapimod will be presented...
TG Therapeutics Launches Phase 2 BRIUMVI Trial
NEW YORK, July 6, 2026 TG Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI®...
Contineum Therapeutics Publishes PIPE-791 Discovery Study
SAN DIEGO, June 30, 2026 Contineum Therapeutics, Inc. announced the publication of its scientific manuscript describing the discovery and...
Ionis Partners with Recordati to Expand Zilganersen Globally
CARLSBAD, Calif., June 25, 2026 Ionis Pharmaceuticals has entered into a landmark global licensing agreement with Recordati to accelerate...
Advertisement
